Nynomic AG (ETR:M7U)
Germany · Delayed Price · Currency is EUR | Market Cap | 71.60M |
| Revenue (ttm) | 97.72M |
| Net Income (ttm) | -6.65M |
| Shares Out | 6.57M |
| EPS (ttm) | -1.01 |
| PE Ratio | n/a |
| Forward PE | 75.17 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,299 |
| Average Volume | 2,685 |
| Open | 10.80 |
| Previous Close | 10.90 |
| Day's Range | 10.40 - 10.90 |
| 52-Week Range | 9.50 - 24.00 |
| Beta | 1.01 |
| RSI | 56.14 |
| Earnings Date | Nov 28, 2025 |
About Nynomic AG
Nynomic AG manufactures and sells products for the spectroscopy, sensor technology, laboratory automation and medical technology, agriculture and environmental technology, and industrial markets worldwide. It offers photonic solutions; OEM components, embedded systems, UV-VIS-NIR systems, and Raman spectrometer systems; miniature spectrometers with fiber-optic cables; MEMS-based spectral sensors; process-integrated optical metrology; turnkey measuring system solutions for the wooden, MDF/HDF plants, OSB works, chipboard plants, paper and pulp m... [Read more]
Financial Performance
Financial StatementsNews
Q3 prelims: Nynomic should have passed the trough; chg. est.
Nynomic's Q3 results show mixed performance with improved order intake and positive EBIT, but FY25 sales guidance trimmed. From 2026 onwards efficiency measures should boost margins. Jetzt den vollstä...
Muted start into the year; gradual improvements expected
Nynomic published a muted start into FY25, largely the result of the ongoing uncertainty within its key end markets. Yet, management remains confident to be able to record gradual improvements through...
Q4 prelims in line, returning to growth in FY25; chg. est.
Nynomic released Q4 prelims largely in line with expectations and a FY25 guidance, which reflects a return to growth. Yet, the expected FY25 growth guidance fell short of market expectations due to on...
Muted prel. Q3 in line with expectations // guidance confirmed
Nynomic released muted preliminary Q3 results in line with our expectations. Key drivers were delayed product call-offs and certain budget-related project postponements into FY25e. Jetzt den vollständ...
H2 marked by postponements, bright mid-term prospects; chg
Nynomic cut its FY24 guidance due to delayed order intakes and project postponements but should return to strong growth from FY25 onwards as reflected by the confirmed mid-term guidance. Jetzt den vol...